Concepts (134)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 24 | 2024 | 1896 | 2.810 |
Why?
|
| Homosexuality, Male | 13 | 2022 | 63 | 2.200 |
Why?
|
| Sexual and Gender Minorities | 7 | 2022 | 63 | 1.560 |
Why?
|
| Transgender Persons | 6 | 2020 | 61 | 1.460 |
Why?
|
| Sexual Partners | 11 | 2021 | 87 | 1.440 |
Why?
|
| Sexual Behavior | 11 | 2024 | 247 | 1.250 |
Why?
|
| Anti-HIV Agents | 4 | 2022 | 315 | 1.030 |
Why?
|
| Sexually Transmitted Diseases | 2 | 2024 | 92 | 1.010 |
Why?
|
| HIV Seropositivity | 2 | 2022 | 121 | 0.890 |
Why?
|
| Self Care | 6 | 2020 | 214 | 0.810 |
Why?
|
| Urban Population | 1 | 2023 | 226 | 0.780 |
Why?
|
| Rural Population | 1 | 2023 | 257 | 0.740 |
Why?
|
| Alcoholism | 1 | 2023 | 231 | 0.730 |
Why?
|
| Telemedicine | 2 | 2023 | 439 | 0.660 |
Why?
|
| Mass Screening | 8 | 2020 | 783 | 0.660 |
Why?
|
| Motivation | 1 | 2020 | 313 | 0.600 |
Why?
|
| Medication Adherence | 7 | 2022 | 400 | 0.570 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2020 | 848 | 0.560 |
Why?
|
| AIDS Serodiagnosis | 4 | 2020 | 56 | 0.540 |
Why?
|
| Self-Examination | 3 | 2020 | 7 | 0.530 |
Why?
|
| Substance-Related Disorders | 3 | 2021 | 459 | 0.390 |
Why?
|
| Veterans | 1 | 2023 | 1754 | 0.380 |
Why?
|
| Reagent Kits, Diagnostic | 2 | 2020 | 53 | 0.350 |
Why?
|
| Pre-Exposure Prophylaxis | 2 | 2021 | 35 | 0.330 |
Why?
|
| Unsafe Sex | 3 | 2024 | 22 | 0.310 |
Why?
|
| Condoms | 3 | 2024 | 49 | 0.310 |
Why?
|
| Puerto Rico | 7 | 2020 | 45 | 0.300 |
Why?
|
| Text Messaging | 2 | 2018 | 31 | 0.290 |
Why?
|
| Safe Sex | 2 | 2024 | 16 | 0.270 |
Why?
|
| Risk-Taking | 3 | 2021 | 94 | 0.250 |
Why?
|
| Students | 2 | 2024 | 251 | 0.230 |
Why?
|
| Anti-Retroviral Agents | 2 | 2022 | 141 | 0.220 |
Why?
|
| Adult | 14 | 2023 | 29482 | 0.210 |
Why?
|
| Risk Reduction Behavior | 2 | 2020 | 142 | 0.200 |
Why?
|
| Male | 18 | 2023 | 61302 | 0.200 |
Why?
|
| Humans | 26 | 2024 | 124802 | 0.190 |
Why?
|
| Female | 19 | 2024 | 66575 | 0.190 |
Why?
|
| Bullying | 1 | 2021 | 14 | 0.190 |
Why?
|
| Acceptance and Commitment Therapy | 1 | 2022 | 40 | 0.180 |
Why?
|
| Computer Security | 2 | 2018 | 26 | 0.180 |
Why?
|
| Depression | 2 | 2020 | 1243 | 0.180 |
Why?
|
| Cannabis | 1 | 2021 | 41 | 0.180 |
Why?
|
| Crime Victims | 1 | 2021 | 59 | 0.180 |
Why?
|
| New York | 4 | 2020 | 69 | 0.170 |
Why?
|
| Smoking Cessation | 1 | 2022 | 197 | 0.170 |
Why?
|
| Sex Workers | 1 | 2020 | 5 | 0.170 |
Why?
|
| Gender Identity | 1 | 2020 | 70 | 0.170 |
Why?
|
| New York City | 4 | 2020 | 59 | 0.170 |
Why?
|
| Violence | 1 | 2020 | 116 | 0.160 |
Why?
|
| Middle Aged | 8 | 2023 | 26727 | 0.160 |
Why?
|
| Young Adult | 7 | 2021 | 8991 | 0.160 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 3447 | 0.160 |
Why?
|
| Interviews as Topic | 4 | 2020 | 377 | 0.150 |
Why?
|
| Aggression | 1 | 2020 | 225 | 0.150 |
Why?
|
| Privacy | 1 | 2018 | 26 | 0.150 |
Why?
|
| Gels | 1 | 2018 | 68 | 0.150 |
Why?
|
| Stereotyping | 1 | 2017 | 19 | 0.140 |
Why?
|
| Health Behavior | 1 | 2020 | 386 | 0.140 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2018 | 70 | 0.140 |
Why?
|
| Personal Satisfaction | 1 | 2018 | 102 | 0.140 |
Why?
|
| Social Stigma | 1 | 2017 | 74 | 0.140 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2018 | 269 | 0.140 |
Why?
|
| Viral Load | 1 | 2018 | 385 | 0.130 |
Why?
|
| Qualitative Research | 4 | 2020 | 548 | 0.130 |
Why?
|
| Vulnerable Populations | 1 | 2018 | 142 | 0.130 |
Why?
|
| Social Media | 1 | 2018 | 105 | 0.130 |
Why?
|
| Anti-Infective Agents | 1 | 2018 | 265 | 0.120 |
Why?
|
| Patient Compliance | 1 | 2018 | 475 | 0.120 |
Why?
|
| Adaptation, Psychological | 1 | 2017 | 451 | 0.110 |
Why?
|
| Cohort Studies | 1 | 2023 | 4786 | 0.110 |
Why?
|
| Patient Selection | 1 | 2018 | 692 | 0.110 |
Why?
|
| Serologic Tests | 2 | 2020 | 118 | 0.090 |
Why?
|
| Adolescent | 4 | 2021 | 19330 | 0.080 |
Why?
|
| Surveys and Questionnaires | 4 | 2020 | 3728 | 0.080 |
Why?
|
| Mental Health | 2 | 2022 | 346 | 0.080 |
Why?
|
| Administration, Rectal | 2 | 2018 | 8 | 0.080 |
Why?
|
| United States | 1 | 2023 | 10875 | 0.070 |
Why?
|
| Alcohol Drinking | 2 | 2020 | 344 | 0.070 |
Why?
|
| Aged | 2 | 2023 | 19693 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 1109 | 0.060 |
Why?
|
| Retrospective Studies | 1 | 2023 | 16290 | 0.060 |
Why?
|
| Sterols | 2 | 1980 | 16 | 0.050 |
Why?
|
| Telephone | 1 | 2022 | 110 | 0.050 |
Why?
|
| Bile Acids and Salts | 2 | 1980 | 245 | 0.040 |
Why?
|
| Focus Groups | 1 | 2021 | 201 | 0.040 |
Why?
|
| Cellulose | 1 | 1980 | 19 | 0.040 |
Why?
|
| Universities | 1 | 2021 | 126 | 0.040 |
Why?
|
| Uganda | 1 | 2020 | 68 | 0.040 |
Why?
|
| Attitude | 1 | 2020 | 115 | 0.040 |
Why?
|
| Dietary Fiber | 1 | 1980 | 74 | 0.040 |
Why?
|
| Patient Preference | 1 | 2020 | 119 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 757 | 0.040 |
Why?
|
| San Francisco | 1 | 2018 | 17 | 0.040 |
Why?
|
| Philadelphia | 1 | 2018 | 25 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2018 | 72 | 0.040 |
Why?
|
| Cholesterol | 2 | 1980 | 536 | 0.040 |
Why?
|
| Boston | 1 | 2018 | 110 | 0.040 |
Why?
|
| Dominican Republic | 1 | 2017 | 16 | 0.040 |
Why?
|
| Self Report | 1 | 2021 | 520 | 0.040 |
Why?
|
| Prejudice | 1 | 2017 | 38 | 0.040 |
Why?
|
| Rectum | 1 | 2018 | 99 | 0.040 |
Why?
|
| Self Efficacy | 1 | 2018 | 199 | 0.040 |
Why?
|
| Confidentiality | 1 | 2018 | 99 | 0.040 |
Why?
|
| Internationality | 1 | 2018 | 131 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2018 | 187 | 0.030 |
Why?
|
| HIV | 1 | 2018 | 180 | 0.030 |
Why?
|
| Truth Disclosure | 1 | 2017 | 103 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2018 | 683 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2017 | 235 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1328 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 422 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 2450 | 0.030 |
Why?
|
| Pandemics | 1 | 2021 | 1104 | 0.030 |
Why?
|
| Quality of Life | 1 | 2021 | 1948 | 0.020 |
Why?
|
| Carrageenan | 1 | 1980 | 4 | 0.010 |
Why?
|
| Medicago sativa | 1 | 1980 | 3 | 0.010 |
Why?
|
| Pectins | 1 | 1980 | 4 | 0.010 |
Why?
|
| Triticum | 1 | 1980 | 34 | 0.010 |
Why?
|
| Feces | 2 | 1980 | 717 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1980 | 574 | 0.010 |
Why?
|
| Dimethylhydrazines | 1 | 1977 | 1 | 0.010 |
Why?
|
| Hydrazines | 1 | 1977 | 29 | 0.010 |
Why?
|
| Rats | 2 | 1980 | 3690 | 0.010 |
Why?
|
| Dietary Fats | 1 | 1977 | 298 | 0.010 |
Why?
|
| Liver | 2 | 1980 | 1764 | 0.010 |
Why?
|
| Animals | 2 | 1980 | 34200 | 0.000 |
Why?
|
| Oils | 1 | 1977 | 6 | 0.000 |
Why?
|
| Deoxycholic Acid | 1 | 1977 | 13 | 0.000 |
Why?
|
| Cholic Acids | 1 | 1977 | 16 | 0.000 |
Why?
|
| Rats, Inbred F344 | 1 | 1977 | 105 | 0.000 |
Why?
|
| Bile | 1 | 1977 | 46 | 0.000 |
Why?
|
| Zea mays | 1 | 1977 | 43 | 0.000 |
Why?
|
| Neoplasms, Experimental | 1 | 1977 | 214 | 0.000 |
Why?
|
| Colonic Neoplasms | 1 | 1977 | 249 | 0.000 |
Why?
|